Horizon Europe Tackling Diseases and Antimicrobial Resistance (AMR) Webinar and Partnering - Cluster 1 / Destination 3 and 5
0 likes293 views
The document outlines a Horizon Europe webinar focused on tackling diseases and antimicrobial resistance, featuring various presentations and networking opportunities for participants. It highlights the structure and funding mechanisms of Horizon Europe, which has a total budget of €95 billion from 2021 to 2027, aiming to enhance research and innovation partnerships. The event includes detailed agendas, expected impacts on health, and opportunities for collaboration among researchers and health organizations across Europe.
Horizon Europe Tackling Diseases and Antimicrobial Resistance (AMR) Webinar and Partnering - Cluster 1 / Destination 3 and 5
- 1. ktn-uk.org/global-alliance Innovate UK KTN Global Alliance in collaboration with Foreign Commonwealth and Development Office (FCDO) 26th November 2021 Horizon Europe – Tackling Disease and AMR Webinar https://ktn-uk.org/news/horizon-europe-work-programme-funding-calls- health/
- 2. Welcome and housekeeping • Due to the large number of people registered all participants will be muted. • After testing your speakers, please do remember to connect your audio by using the “Join Audio” icon at the bottom left of the screen or dial in via phone using the number provided in the joining instructions. • If you have any technical problems, please use the chat to seek advice from the host (Jess Dobbyne). • Questions and Answers Please also use the chat function • Please use the chat function to introduce yourself, please note due to GDPR we cannot share the chat. Capture what you need PLEASE NOTE – THE WEBINAR IS BEING RECORDED The recording and slides will be made available via the KTN website Welcome to our Horizon Europe event series in collaboration with FCDO and Innovate UK Horizon Tackling Disease and AMR It’s World AMR week!
- 3. The Agenda • 09:30 – Introduction & Aims of the Day | Jane Watkins, KTN & Frances Wood , Regional Director for the UK Government Science and Innovation Network covering Europe, Russia and Turkey, FCDO • 09:40 – Introduction to Horizon Europe | Jane Watkins, KTN • 09:50 – Overview of Health work programme (2022 calls under Destination 3. Tackling diseases and reducing disease burden) | Kay Duggan-Walls, Health Research Board (NRB), Ireland • 10:05 – Overview of the JPIAMR call | Laura Plant, JPIAMR Secretariat, Swedish Research Council • 10:20 – Q&A • 10.30 BREAK • 10:40 – Case study | Anita Hogg, Medicines Optimisation Innovation Centre (MOIC) • 10:50 – Getting started and finding the right partners? | Jo Frost, UK Health NCP for Industry, Innovate UK • 11:15 – Pitching Sessions • 12:30 – Lunch • 13:00 – Networking via Meeting Mojo & NCP Surgery
- 4. • NCP 1:1 meetings from 1-2.30pm (GMT) National Contact Point Contact Country Ewa Szkiladz Narodowe Centrum Badań i Rozwoju, Poland Valentina Albarani Union Wallonne des Entreprises (UWE), Belgium (Wallonie) Živilė Ruželė Research Council of Lithuania (LMT), Lithuania Doris Bell Deutsches Zentrum für Luft- und Raumfahrt e. V. (DLR), Germany Sasha Hugentobler Euresearch Network Office, Switzerland Patricia McCrory QUB, Northern Ireland Kay Duggan-Walls Health Research Board, Ireland (available 1-1.45pm) Sofia Magdalena Anderholm Strand The Research Council of Norway, Norway Joanna Frost Innovate UK UKRI, UK The link for people to find NCPs in other countries is https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/support/ncp/.
- 5. Networking and Connecting – Pitches Instructions and Running Order • The pitch presentations will begin at 11.15 am. • We will load and control your slides. • We will unmute you to allow you to present your slides. Please ensure you have connected your audio and your microphone before the pitch sessions begin. You can test your speaker and microphone by clicking the arrow next to the microphone. This will bring up a dropdown of options, including ‘Test speaker & microphone.’ • The pitches will run in alphabetical order of organisation. • You will have opportunity to pitch for 2 minutes.
- 6. Pitch Running order Organisation Speaker Aston University Jonathan Cox Aquarius Population Health Limited Katy Turner Biocrucible David G Brooks Centre of Postgraduate Medical Education Damian Gawel Genemill J. Enrique Salcedo-Sora IBIMA Aitor Rando Rodán IBISS Ivana Stojanović Imperial College London Leonid Chindelevitch Medicines Discovery Catapult Helen Bright Open University of Israel Ofer Reany Oslo Hospital University James Booth Oxford Vacmedix William Finch Scotland’s Rural College Nicola Holden University of Aberdeen Soumya Palliyil University of Kent Jennifer Hiscock University of Liverpool Dr Qibo Zhang
- 7. Networking and Connecting – Meeting mojo • This is a separate platform to Zoom • You can organise 1:1 meetings with other registered users • You will be able to create your profile, search other users’ profiles and book video chat meetings via the platform. • You can search by organisation, by individual or by key word. • Don’t forget to confirm your requested meetings! • https://he-amr.meeting-mojo.com/ • Opportunity to network this afternoon. Will remain open until the for 1 week (Close 3rd December) we can keep going if active!
- 8. Introduction and Aims of the Day Frances Wood - Regional Director for the UK Government Science and Innovation Network covering Europe, Russia and Turkey, FCDO
- 9. ktn-uk.org/global-alliance Horizon Europe Jane Watkins European Programmes Innovate UK KTN
- 10. • Funding programmes created by the European Union/European Commission to support and foster research and innovation • Began in 1984 and each last for 7 years and align to the EU’s Multiannual Financial Framework (MFF) Horizon 2020 • The previous Framework Programme (FP). It began in 2014 and had its last call for proposals in 2020. Total budget for Horizon 2020 was ~ €80bn Horizon Europe • The 9th FP and successor to Horizon 2020 will run from 2021 to 2027 • €95B total budget - Work Programmes are available European Framework Programmes The UK has agreed to Associate to Horizon Europe
- 11. UK ‘Association’means continued UK participation The UK has agreed to Associate to Horizon Europe 11 •UK entities will have equivalent participation rights to those from Member States •UK entities can lead projects as coordinators •UK has continued access to Horizon Europe research and innovation funding, infrastructure and markets •Able to access funding from all parts of the Programme including the ERC (European Research Council), MSCA (Marie Skłodowska-Curie Actions), Partnerships, the EIT (European Institute of Innovation and Technology), the direct actions of the JRC (Joint Research Centre). The UK will be an associate to the COST programme and to EURATOM and ITER. Can access the majority of the EIC (European Innovation Council) the except the EIC Accelerator equity fund •Work programme level exclusions only in exceptional and justifiable cases (e.g., some Defence & Security) •Participation and influence on programme governance structures (e.g. programme committees) •UK experts can continue to take part in peer review (register as an expert here) •The ‘Associated Countries’ concept is not new - Horizon 2020 had 16 Associated Countries including Israel, Norway and Turkey
- 12. EU confirmation of UK participation European Commission Q&A on the UK’s Participation in Horizon Europe UK Association “UK participants will have the same rights as EU participants…” “UK entities are eligible for funding at the same rates and under the same conditions” “They can lead project consortia”
- 13. Size of the prize – Horizon 2020 UK stats (EU average 11.91%)
- 14. • €95.5bn total funding agreed for 2021-2027 • NB budget figures exclude UK and other Associate Country contributions • Canada, Japan, Australia etc. Interested status (TBC) Horizon Europe structure
- 15. • Research and innovation actions (RIA) • Innovation actions (IA) • Coordination and support actions (CSA) • RIA – Research and Innovation Actions – up to 100% funding rate. Page limit usually 45 pages • IA – Innovation Actions – up to 70% funding rate (except non-profit, 100% applies). Page limit usually 45 pages • CSA – Coordination and Support Actions – up to 100% funding rate. Page limit usually 30 pages Main Types of Project Main Project Types • Excellence • Impact • Quality and Efficiency of implementation Award Criteria
- 16. Why participate? High funding rate: up to 100% of eligible costs The only guaranteed and predictable funding for certain sectors No artificial constraints (consortium size, budget allocation to non-industrials...) Access to cutting edge technologies, infrastructure & talent Increased visibility at EU & global level Build domestic and international partners/customers Solving global grand challenges through collaborative R&D Influence standards, regulations and research policies Creating UK jobs, growth and stronger supply chains
- 19. Networking and Connecting – Meeting mojo • This is a separate platform to Zoom • You can organise 1:1 meetings with other registered users • You will be able to create your profile, search other users’ profiles and book video chat meetings via the platform. • You can search by organisation, by individual or by key word. • Don’t forget to confirm your requested meetings! • https://he-amr.meeting-mojo.com/ • Opportunity to network this afternoon. Will remain open until the for 1 week (Close 3rd December) we can keep going if active! • Networking cards (if you haven’t pitch there is also opportunity to share your expertise looking for partners or joining a consortium • https://drive.google.com/drive/folders/1808EnJFpxSAtz8tqdV9wxcTruSWuuyod?usp=s haring
- 20. • NCP 1:1 meetings from 1-2.30pm (GMT) National Contact Point Contact Country Ewa Szkiladz Narodowe Centrum Badań i Rozwoju, Poland Valentina Albarani Union Wallonne des Entreprises (UWE), Belgium (Wallonie) Živilė Ruželė Research Council of Lithuania (LMT), Lithuania Doris Bell Deutsches Zentrum für Luft- und Raumfahrt e. V. (DLR), Germany Sasha Hugentobler Euresearch Network Office, Switzerland Patricia McCrory QUB, Northern Ireland Kay Duggan-Walls Health Research Board, Ireland (available 1-1.45pm) Sofia Magdalena Anderholm Strand The Research Council of Norway, Norway Joanna Frost Innovate UK UKRI, UK The link for people to find NCPs in other countries is https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/support/ncp/.
- 22. Horizon Europe Tackling Diseases and Antimicrobial Resistance(AMR) Cluster 1 Destinations 3 and 5 Kay Duggan-Walls, NCP Horizon Europe, Cluster 1 Health
- 23. Destination 3 - Expected Impacts Tackling diseases and reducing disease burden Expected Impacts • For health the burden of disease in the EU and worldwide will be reduced through effective disease management, including development and integration of innovative diagnostic and therapeutic approaches, personalised medicine approaches, digital and other people-centre solutions to health and care • Patients should be diagnosed early and accurately and receive effective cost-efficient and affordable treatment, including for rare diseases • Premature mortality from non-communicable diseases reduced by one third by 2030 • Healthcare systems should be better prepared to respond to health emergencies • Patients and citizens should be knowledgeable about disease threats, involved and empowered to make and shape decisions for their health
- 24. Destination 3 Topics Topics by 'Destination' or 'Expected Impact' 2022 Instrument Single Stage or Two-stage No. Proposals to be funded Destination 3. Tackling diseases and reducing disease burden *Call HORIZON-HLTH-2022-DISEASE-06-two-stage – Tackling diseases (Two Stage - 2022) HORIZON-HLTH-2022-DISEASE-06-02-two-stage: Pre-clinical development of the next generation immunotherapies for diseases or disorders with unmet medical need 60 RIA Two-Stage 10 (€6M) HORIZON-HLTH-2022-DISEASE-06-03-two-stage: Vaccines 2.0 - developing the next generation of vaccines 40 RIA Two-Stage 5 (€8M) HORIZON-HLTH-2022-DISEASE-06-04-two-stage: Development of new effective therapies for rare diseases 60 RIA Two-Stage 8 (€8M) *Call HORIZON-HLTH-2022-DISEASE-07 – Tackling diseases (Single Stage -2022) HORIZON-HLTH-2022-DISEASE-07-02: Pandemic Preparedness 10 RIA Single Stage 3 (€3M) Opening 12 Jan HORIZON-HLTH-2022-DISEASE-07-03: Non-communicable diseases risk reduction in adolescence and youth 25 RIA Single Stage 8 (€3M)
- 25. Destination 5 – Expected Impacts Unlocking the full potential of new tools, technologies & digital solutions for a healthy society Expected Impacts • Contribute to Europe’s: • Scientific and technological expertise and know how • its capabilities for innovation in new tools • Its ability to take-up, scale-up and integrate innovation in health and care • Enable researchers, innovators and healthcare providers to use health data and AI supported decision-making in a secure ethical acceptable and trust worthy manner • Citizens should benefit from • Safer, more efficient, cost effective and affordable tools, technologies and digital solutions • For effective personalised disease prevention, diagnosis treatment and monitoring for better patient outcome and well-being • In particular through increasingly shared health resources
- 26. Destination 5 Topic Topics by 'Destination' or 'Expected Impact' 2022 Instrument Single Stage or Two-stage No. Proposals to be funded Destination 5. Unlocking the full potential of new tools, technologies & digital solutions for a healthy society Call HORIZON-HLTH-2022-TOOL-11 – Tools and technologies for a healthy society (Single Stage - 2022) HORIZON-HLTH-2022-TOOL-11-02: New methods for the effective use of real- world data and/or synthetic data in regulatory decision-making and/or in health technology assessment 35 RIA Single Stage 5 (€7M)
- 27. Contact Kay Duggan-Walls, MSc NCP Health Health Research Board [email protected] Tel (01) 2345 187 085 8868183
- 28. www.jpiamr.eu twitter.com/JPIAMR facebook.com/JPIAMR www.jpiamr.eu twitter.com/JPIAMR facebook.com/JPIAMR JPIAMR: Supporting Transnational Research Laura Plant Senior Research Officer JPIAMR Secretariat
- 29. www.jpiamr.eu twitter.com/JPIAMR facebook.com/JPIAMR JPIAMR: A global organisation The European Commission (DG Research) is a full non- voting member 28 member countries Coordinates AMR research and funding One Health perspective International collaborative platform
- 30. www.jpiamr.eu twitter.com/JPIAMR facebook.com/JPIAMR SRIA: Strategic Research and Innovation Agenda Understanding and preventing the transmission of antimicrobial resistance Transmission Discovery of new antimicrobials and therapeutic alternatives, and the improvement of current antimicrobials and treatment regimens Therapeutics The role of the environment in the persistence, selection and spread of antimicrobial resistance Environment Optimisation of surveillance systems to understand the drivers and burden of antimicrobial resistance in a One Health perspective Surveillance Development and improvement of diagnostics to improve the use of antimicrobials and alternatives to antimicrobials Diagnostics Investigation and improvement of infection prevention and control measures in One Health settings Interventions
- 31. www.jpiamr.eu twitter.com/JPIAMR facebook.com/JPIAMR JPIAMR: A global One Health AMR Research Funder 23% 31% 11% 5% 9% 21% Therapeutics • Discovery of new antimicrobials and therapeutic alternatives • New target identification • Repurposing of drugs Transmission • Transmission mechanisms and routes • Strategies to inhibit or reduce AMR transmission • Risk assessment Surveillance • Improvement of Surveillance tools and technologies • Standardisation of methods Diagnostics • New rapid diagnostics and point-of-care techniques • AMR detection in multiple reservoirs Interventions • Interventions for infection prevention and control measures Environment • Transmission routes in environment • Surveillance of non-human AMR reservoirs (wildlife, wastewater)
- 32. www.jpiamr.eu twitter.com/JPIAMR facebook.com/JPIAMR Researcher Location Overview of JPIAMR supported research >100 M€ Total Investment 1313 Researchers › From 71 different countries Networks Projects 118 80 38 32 LMICs involved 80 researchers from LMICs 25 research project and networks with LMIC elements in their research scope One Health perspective Projects with One Health aspect 38%
- 33. www.jpiamr.eu twitter.com/JPIAMR facebook.com/JPIAMR Roadmap of Actions 2019-2024
- 34. www.jpiamr.eu twitter.com/JPIAMR facebook.com/JPIAMR JPIAMR Roadmap 2021-2024 JPIAMR Activity 2021/22 2022/23 2023/24 Research Calls Transmission and Interventions ONGOING: One Health interventions to prevent or reduce the development and transmission of AMR Therapeutics IN DEVELOPMENT: Optimising existing drugs or drug combinations for the prevention and treatment of infections Diagnostics and Surveillance Development of innovative, digital technologies for collection of microbiological and antibiotic data Network Calls Diagnostics and Surveillance IN DEVELOPMENT: Network Call Interventions Building Bridges between One Health areas to implement interventions
- 35. www.jpiamr.eu twitter.com/JPIAMR facebook.com/JPIAMR Call for Research Projects Call for Research Networks Nature of the call Project calls support multi-national translational research collaborations for AMR research scientists that includes (but not limited to) basic research, pre-clinical and phase 1 clinical trials Networks of AMR experts, scientists and policy makers to enhance resource alignment, capacity building and maximise existing and future efforts to combat AMR through multinational collaborations Expected outputs and outcomes Research findings White papers, views, guidelines, and/or best practice frameworks, and others Application process 2-stage application 1-stage application Size of the consortium 3-7 researchers from at least 3 JPIAMR (or fundable) countries Typically 15 partners from at least 10 different countries Funding amount and details • Coordinator and partners funded by their national funding agencies • Funding amount according to national guidelines • Coordinator is funded by their national funding agency • Funding amount 50-200k€ (call dependent) JPIAMR funding mechanisms
- 36. 14th JPIAMR Call Disrupting Drug Resistance Using Innovative Design (DRUID) .. • Participating countries: Belgium (FWO, FNRS), Canada (CIHR), Czech Republic (MEYS), Estonia (ETAg), France (ANR), Germany (BMBF), Hungary (NKFIH), Israel (CSO-MOH), Italy (FRRB, It- MoH), Latvia (VIAA, LZP), Lithuania (RCL), Moldova (ANCD), Poland (NCN, NCBR), Spain (AEI, ISCIII), Sweden (SRC, SIDA, Vinnova), Switzerland (SNSF), United Kingdom (UKRI-MRC, UKRI- BBSRC, UKRI-EPSRC) • Estimated call budget: € 17 million • Call opens: January 11 2022 (planned) • Information: www.jpiamr.eu and @jpiamr
- 37. 14th JPIAMR Call Disrupting Drug Resistance Using Innovative Design (DRUID) • Aim: to improve the treatment of bacterial and fungal infections (including co-infection) and/or the prevention of the emergence/spread of resistance in humans, animals or plants through the improvement of the efficacy, specificity, delivery, combinations and/or repurposing of drugs and plant protection agents.
- 38. 14th JPIAMR Call Disrupting Drug Resistance Using Innovative Design (DRUID) • Proposals should focus on licenced antimicrobial agents (antibiotics/antifungals) or agents under pre-clinical and/or early clinical development, and should address at least one of the following topics: • Improvement of drug/plant protection agent efficacy and/or specificity through chemical modifications (including hit to lead optimisation) • Drug/plant protection agent repurposing; • Optimisation of drug/plant protection agent combinations, alone or with adjunct therapies (including therapeutic vaccines); • Design and implementation of new strategies (including optimisation of drug doses) for improved application, efficacy and delivery of single or combinations of antimicrobials; • Design and implementation of innovative tools, including novel chemistry and/or new materials for improved application, efficacy and delivery of antimicrobials.
- 39. 14th JPIAMR Call Disrupting Drug Resistance Using Innovative Design (DRUID) • Proposals can focus on one or more of the three “One-Health” settings: • Human Health • Animal Health (including wildlife, livestock, fishes, and companion animals) • Plants (including trees and crops) • Participation of end-users, stakeholders and companies is encouraged. • The following sub-topics are out of scope of the call: • Antiviral and antiparasitic agents • Discovery and/or screening of new compounds, new vaccines and/or new targets • Proposals solely aiming to develop new diagnostics or new companion diagnostics (companion diagnostics in evaluation of the antimicrobials can be examined but they should not be the main topic of the proposal.)
- 40. 14th JPIAMR Call Disrupting Drug Resistance Using Innovative Design (DRUID) Webinar for applicants • 25th of January 2022 • Present the call and the partner search tool • Representatives from funders participating in the call will answer questions live Partner Search Tool • A match-making tool to facilitate networking and the creation of consortia • Will be open on the day of the launch of the call • The tool can be consulted for several purposes: • Partner looking for project: As individual researcher or a representative of a lab or research team, searching for a project to join. • Project looking for partner: If you want to build a consortium around an existing project and want to find partners for your project ideas.
- 41. 15th JPIAMR Call Diagnostics and Surveillance Networks • Participating JPIAMR - ACTION members (to date): Egypt (ASRT), Estonia (ETAg), France (ANR), Italy (It-MoH), Lithuania (RCL), Moldova (ANCD), Netherlands (ZonMw), Norway (RCN), Spain (ISCIII), Sweden (SRC), United Kingdom (UKRI-MRC) • Funding: € 50,000 per Network • Call opens in April 2022 • Information: www.jpiamr.eu and @jpiamr
- 42. 15th JPIAMR Call Diagnostics and Surveillance Networks • Aim: to assemble networks of leading experts and stakeholders with an intent to facilitate the development, optimisation and use of diagnostic and surveillance tools, technologies and systems.
- 43. 15th JPIAMR Call Diagnostics and Surveillance Networks • Networks should work towards the conceptualisation of ideas in order to provide white papers, guidance documents and/or best practices/roadmaps and evidence frameworks to identify key questions to be addressed and/or potential solutions to overcome barriers to enhanced surveillance and advanced diagnostics to reduce the burden of AMR.
- 44. 15th JPIAMR Call Diagnostics and Surveillance Networks • 22 March 2022 – Detailed pre-announcement text available • 12 April 2022 – Call opens • 28 April 2022 – Webinar for applicants • 14 June 2022 – Proposal deadline
- 45. www.jpiamr.eu twitter.com/JPIAMR facebook.com/JPIAMR • Register on the partner search tool when the call opens • Participate in the call webinars • Subscribe to JPIAMRs newsletter • Keep updated on national rules via the JPIAMR call webpage and any additional national funding agency webpages What can you do to prepare?
- 46. www.jpiamr.eu twitter.com/JPIAMR facebook.com/JPIAMR www.jpiamr.eu twitter.com/JPIAMR facebook.com/JPIAMR For more information: Subscribe to the JPIAMR newsletter Follow JPIAMR on social media Follow any updates from national agencies Information will be available early in 2022.
- 48. European funding… Hints and tips for success Anita Hogg Lead, Medicines Optimisation Innovation Centre (MOIC)
- 50. MOIC tips 1. Finding partners 2. Identifying call topic 3. Writing proposal 4. Budget 5. Grant agreement partnership (GAP) signing and grant agreement
- 51. 1. Finding partners….create networks Denmark Norway Ireland Sweden UK Netherlands Egypt Estonia Jordan New Zealand Palestine Poland Spain
- 54. Create networks - locally
- 55. 2. Identifying call topic
- 56. 3. Writing proposal Varies depending on consortium – be flexible! Maximise lead in time, GANTT chart, PIC, populate Partner commitment up front - accountable! Dates in diaries (weekly!) & clear actions Strong consortium Know grant requirements & align
- 57. Writing proposal Strong consortium lead and WP leads Align partners expertise with work packages European hot topics (medicines in pregnancy and breastfeeding) Differences in structures, policy and practice Clearly define deliverables that you can deliver! Terminology (medicines optimisation, medicines management, pharmaceutical care, clinical pharmacy)
- 58. Be familiar with portal…
- 59. 4. Budget Consult local finance team early* Maximum available? Funding level (eg 100%)? Eligible costs? PPM - number of ways to calculate Negotiation within consortium Be REALISTIC *No research office eg SME contact NI/UK Contact Point for steer
- 60. 5. Grant agreement partnership and signing agreement
- 61. 5. Grant agreement partnership and signing grant agreement COMPLEX Difficult for MOIC (new) Consider at proposal stage Good governance LEAR LSIGN FSIGN
- 62. Unsuccessful….
- 63. Keep going….. Review feedback & connect with partners Resubmit/repurpose for another grant
- 64. Success….
- 66. Where are we now? • MEDSAFE • Interested in other Cluster 1 (Health) calls • April 2022
- 67. Final tips… • Draw on experience of others • Seek help if required • Start small, partner well - progress • Very competitive – don’t be put off (some only fund 5!) • High score but not funded • GO FOR IT!
- 70. Getting started and finding partners 26Nov2021 JoFrost–UKHorizonEuropeNationalContactPoint(NCP) ([email protected]) Slides happily shared NCPs in other countries Please sign up our UK newsletter here for the latest Horizon Europe health funding opportunities news
- 71. Agenda 2 • National Contact Points • UK Government ‘Pump Priming’ funding • Project types • Eligibility criteria, Associated Countries, International participation • Building a consortium • Funding partners • Tips
- 72. What is a National Contact Point (NCP)? NCP Businesses RTOs Academia UK Gov EU Commission Global R&I network UK NCP network: Team of sector specific public servants whose role it is to provide free support to UK participants to Horizon Europe International NCP network: support in Europe and the rest of the World NCP services vary in each country/sector, but typically include: Jo Frost UK Health NCP for industry Informing, awareness raising – on Horizon Europe and other EU programmes Assisting, advising and training – to improve the quality of Horizon Europe proposals Signpos6ng and coopera6on – direct to relevant support and work with each other to support consor<um development Please sign up for our newsletter here for the latest Horizon Europe health funding opportunities news
- 73. New: UK Government ‘Pump Priming’ Funding 4 • For UK organisations and their consortia (in any eligible country) preparing Horizon Europe proposals • Applicants will need to identify a specific upcoming call (in Pillar II) as the focus of their proposed collaboration with the goal of submitting an application to that upcoming call, building on this pump priming funding. • Up to £10,000 available per proposal • Next deadline 8 Dec then every 2 weeks (until all call budget is used) • Call website • LinkedIn post – please read comments thread for extra info on how funding can be used/who can be funded The pump priming call is run by The British Academy, the Science & Innovation Network in Europe, UK Research and Innovation and KTN with the support of The Academy of Medical Sciences & the Royal Academy of Engineering
- 74. Main Project Types (in Health Cluster) 5 Research and innovation actions (RIA) • Activities aiming primarily to establish new knowledge or to explore the feasibility of a new or improved technology, product, process, service or solution. • May include basic and applied research, technology development and integration, testing, demonstration and validation on a small-scale prototype in a laboratory or simulated environment. Innovation actions (IA) • Activities directly aimed at producing plans and arrangements or designs for new, altered or improved products, processes or services • Possibly including prototyping, testing, demonstrating, piloting, large-scale product validation and market replication. Coordination and support actions (CSA) • Activities contributing to the objectives of the Horizon Europe Programme, excluding R&I activities (with some exceptions – see the General Annexes to the Work Programme) • Pre-commercial procurement actions (PCP) • Public procurement of innovative solutions actions (PPI) From the Work Programme 2021-2022 General Annexes
- 75. Eligibility Eligibility for funding is usually (unless otherwise stated in the call): • Any type of legal entity established in EU Member State (MS) or ~18 Associated Countries (AC) • Legal entities from ~115 Low & Middle Income Countries (LMICs) if country listed here • International European research organisations • You can also get funding for organisations in other higher income countries occasionally: • If it is specified in your call topic, or • If their participation is essential for the project. • US organisations funded in Health Cluster only (✔RIA and IA ❌CSA unless mentioned in call topic) Eligibility for participation is usually (unless otherwise stated in the call): • legal entities from outside EU MS/AC (known as ‘third countries’) can often participate too, although they would normally need to fund their own participation (unless one of the above exceptions applies)
- 76. High income countries outside Europe/AC For higher income countries outside of Europe (which are not associated countries): • there are often national contact points who will be able to advise if any local funding is available to enable them to participate. Sometimes the local funding is available to allow their researchers to participate in all calls, sometimes just for specific call topics, and sometimes funding is not available locally. • for the previous programme, Horizon 2020 the European Commission has some “country page” specific guidance (e.g. Brazil, India and China) with info and contacts. These documents are not yet available for Horizon Europe, but there is some info here. Switzerland: • For 2021 and 2022 calls, Swiss entities can participate in collaborative projects (including RIAs and IAs) as a Third Party ‘Associated Partner’ • Funding provided by Swiss government: Financial Guarantee for 2021 and 2022 • Dedicated website including FAQs: https://www.horizon-europe.ch • You can find templates and checklists on how to add an Associated Partner and its budget and other related issues on this website
- 77. Consortia Size Minimum consortium size • Collaborative projects: Usually a consortium must have a minimum of 3 independent legal entities, each established in different EU Member States (MS) or Associated Countries (AC), with at least 1 of them established in a MS • Coordination & Support Actions: One or more legal entities, which may be established in a MS, AC, or in exceptional cases and if provided for in the specific call conditions, in another third country.
- 78. What do ideal partners look like? • Expert in their area • Enthusias.c and commi3ed • Responsive to coordinator’s requests, able to communicate well (think about languages too?) • Trustable
- 79. How to start building a consortium? • What expertise is needed for the project? (Read the call topic very carefully) • Which sectors and disciplines are needed? (Academia, Industry, stakeholders, patient groups…?) • Are there people you have worked with before or know with suitable expertise? Friends of friends? • What expertise is still needed? Where might you find good partners with this expertise? • How will people/organisations be involved? Partners? Advisory groups? To feed in/disseminate to? • Think about ‘European Added value’ • Good to have some partners/orgs. with EU/collaborative experience (Especially as coordinator?)
- 80. Formal consortium building mechanisms Some also have other tools/partner databases (e.g. EEN/EDGE, Innovative Medicines/Health Initiative Participant portal – Every topic has a ‘Partner Search’ function where you can upload your profile and review others that have done so Brokerage events – European Commission, Enterprise Europe Network, UK’s KTN, NCPs from around Europe, Technology Platforms etc will virtual hold events with e.g., Meeting Mojo, B2Match Partner Search – under the How to participate tab on the EU funding and tenders portal where you can search for past projects and organisations Horizon Europe 2022 Health Calls – Brokerage Event on 29 Oct – website still open CORDIS – a more useful way of finding past projects and participants and allows you to contact them Searching the formal consortium building mechanisms is a bit like looking for a needle in a haystack – they all look like needles so finding the ones for you can be difficult
- 81. 2022 Health Calls – Infoday and Partnering Events • 28 Oct 2021: European Commission Health Calls infoday on 28 Oct (presentations + Q&A avail to watch) • 29 Oct 2021: Main partnering event for Health 2022 calls (site live until end Jan 2022) organised by Health NCPs, European Commission, EEN • On the marketplace tab you can see who have entered info for each topic – you will need to turn on the ‘project cooperation’ toggle, then can tick topics
- 82. 2022 Health Calls – Infoday and Partnering Events • On the participants tab you can also see which organisations are interested in each call topic and can also search by country or organisation type (may include some organisations extra not on the ‘marketplace’ tab) • Joint Programming Initiative AMR (JPI AMR) 2022 Call on Therapeutics ‘Disrupting drug resistance using innovative design’ • 25 Jan 2022 Webinar and presentation on partner search tool
- 83. EU Participant Portal – Call Topic pages Demo Example…
- 84. Demo UKRI webpage with guidance on how to use the partner search tool EU Participant Portal – Call Topic pages
- 88. Cluster 1 (Health) NCP partnering form Partnering form • Can be circulated at any time • Contact your NCP for a copy: • MRC UK Health NCP for academia ([email protected]) • Jo Frost UK Health NCP for industry • NCPs in other countries
- 89. The best ways to form winning teams Being an effective networker is much more useful than submitting a profile into a portal and awaiting contacts. Don’t wait to be invited to the party, push yourself forward • Use your existing professional networks – if you don’t know who the sector leaders are in Europe then you should find out • Use Linked In to connect to people from possible consortium partners • Search CORDIS for previous, related projects and contact the participants. All projects must disseminate their results and often hold workshops, etc. • Join the relevant networks, associations and partnerships • Be an active member – say ‘hi’ when you join the virtual room. Ask questions, support others’ opinions, act as if you are already well known to all in the virtual room • Volunteer to draft working papers, take notes, send in useful information – be helpful • Speak up at workshops – demonstrate Thought Leadership • Show that you would be a valuable partner for collaborative projects and that without you they won’t win – you have the secret sauce that is necessary for their success
- 90. What constitutes a winning consortium? One that can deliver the expected outcomes within the stated scope and budget (and give the evaluators confidence that they can) There is no ‘typical’ or ‘model’ consortium structure/membership, it depends what is needed for the call topic. • Any type of organisation can be funded by Horizon Europe. It is common to see universities, big business, small business, research and technologies organisations, local/national authorities, patient groups, charities, policy makers all within the one consortium. Useful to include exploitation partners – someone who is going to take the outputs of the project and actually implement them (e.g. in policy/industry/hospitals/patient care/civil society/cultural and creative sectors) to show immediate impact. Many Health cluster call topics mention involving patient groups too. Useful to include the end user community, possibly as an advisory board or associate partners (not direct beneficiaries but costs e.g. travel can be included in ‘other costs’), again to demonstrate their involvement in the design of your project so it suits their needs, and also to show a route to your project having impact.
- 91. Hints and Tips – Building a consortium Quesons to think about: Who has the best experse/reputaon? Who should you approach to be part of a consorum? Not everyone has to have the same size role Don’t include partners because you think it will look good or to pad the proposal out - each partner should have a clear and defined purpose. Have a good balance of countries – more than ~30% if the budget going to one country might be of concern to the evaluators
- 92. Thank you Slides happily shared
- 94. Networking and Connecting – Pitches Instructions and Running Order • We will load and control your slides. • We will unmute you to allow you to present your slides. Please ensure you have connected your audio and your microphone before the pitch sessions begin. You can test your speaker and microphone by clicking the arrow next to the microphone. This will bring up a dropdown of options, including ‘Test speaker & microphone.’ • The pitches will run in alphabetical order of organisation. • You will have opportunity to pitch for 2 minutes
- 95. Pitch Running Order Organisation Speaker Aston University (UK) Jonathan Cox Aquarius Population Health Limited (UK) Katy Turner Biocrucible (UK) David G Brooks Centre of Postgraduate Medical Education (PL) Damian Gawel COAD University of Queensland, Australia Mark Blaskovich Genemill (UK) J. Enrique Salcedo-Sora IBIMA (ES) Aitor Rando Rodán IBISS (RS) Ivana Stojanović Imperial College London (UK) Leonid Chindelevitch Medicines Discovery Catapult (UK) Helen Bright Open University of Israel (IL) Ofer Reany Oslo Hospital University (NO) James Booth Oxford Vacmedix (UK) William Finch Scotland’s Rural College (UK) Nicola Holden University of Aberdeen (UK) Soumya Palliyil University of Kent (UK) Jennifer Hiscock University of Liverpool (UK) Dr Qibo Zhang
- 96. Mycobacterium abscessus • Multidrug resistant: no truly effective treatment regime • Prevalent in Cystic Fibrosis patients • We have a large bank of clinical isolates across all 3 subspecies • Combinations including β- lactam/β-lactamase inhibitor combinations Antibiotic Discovery at Aston University Mycobacterium tuberculosis • Non-replicating persistent Mtb drug discovery • Currently no drugs for treating latent TB, only active • Developed the first physiologically relevant assay for NRP-TB drug screening Dr Jonathan Cox, [email protected] Business collaborations ESKAPE and WHO Priority Pathogens
- 97. Proposed Approach We propose to support bids as a partner, by providing qualitative and quantitative insight, health economics and modelling as applied to infectious diseases and diagnostics including AMR. We can address how to understand the burden and unmet need of AMR from a disease, diagnostic and system perspective, including One health. We anticipate partnering with academic, industry, charity, healthcare providers and other partners to provide our specialist expertise in generating evidence broadly around health economics of interventions for AMR. Organisational Capabilities We bring expertise in health economics and modelling applied to infectious diseases and diagnostics and AMR. We provide flexible, dynamic and high-quality solutions. We generate evidence to inform and support rational decision-making and policy in healthcare. We support the planning, evaluation and implementation of better and more efficient healthcare to improve patient care and outcomes. Experience • Multidisciplinary team works across sectors and disease areas • Use creative approaches in seeking solutions • Flexible and responsive to our partners’ needs, and champion collaborative working and close partnerships to deliver true value when exploring challenges • Experience of being co-applicant on successful grant-funded projects (SBRI, Innovate UK, NIHR, etc.) • Extensive experience in AMR, including numerous publications and contributor to the O'Neill Review. Administrative Information We plan to be a partner Horizon Europe Tackling Diseases and Antimicrobial Resistance (AMR) Aquarius Population Health Limited Unit 29 Tileyard Studios London N7 9AH UK +44 (0) 207 993 2930 [email protected]
- 98. Proposed Approach Problem: Existing diagnostics are either lab-based, slow or inaccurate Solution: Rapidly deployable consumer molecular diagnostic based on isothermal RPA-based amplification offering: • Single copy-sensitivity • Multiplexable • Results in 15’ • High usability • Low CoGs <€10 • Highly manufacturable Partners sought: Engineering (mech & elec), clinical collaborators and KoLs Organisational Capabilities As part of Sapphiros KKR, Biocrucible has a strong financial footing and capabilities in: • Assay development & integration • Protein manufacture • Clinical & Regulatory • Consumable manufacturing process • Commercialisation & market access • Initial Sars-CoV2 launch May 2022 Experience 20 years experience in device and drug development inc. C-level. Previous experience of FP7 grants. Biocrucible/Sapphiros team of ~30 scientists & industry leaders ex TwistDx, Alere and Smith & Nephew. Collaborations with leading academic sites in UK for initial Sars-CoV2 product Administrative Information Partner status preferred Dr David G Brooks [email protected] +44 1223 792693 UK PIC: 888432022 C1, D3 - Pandemic Preparedness
- 99. Proposed aaproach Our scientific interests concern various aspects of cell biology. One of our goals is to discover and study novel pathogenicity factors of UPEC (uropathogenic Escherichia coli). We are also focused on elucidating mechanisms that allow bacterial strains to survive in unfavorable conditions (e.g., attack of the human immune cells), including studying the role of stress response systems, which play an important role in controlling bacterial survival. An important aspect is to deliver potential (including immune- based) treatments for UPEC-mediated UTI. Organisational Capabilities We offer to provide a preclinical analysis of potential anti-bug treatment tools/agents in both in vitro and in vivo (mice) environments. We have access to certified vivarium and MGM laboratories to perform all necessary analyses. Organisation type – Academic Experience In our study we use both in vitro (tissue cultures) and in vivo (mice) UTI models. We offer extensive expertise in molecular biology techniques, including cloning, gene knock-out/replacement, mutagenesis, RNAseq, etc. We collaborate closely with our NIEHS (USA) partners. Members of our team previously gained experience at the National Institute of Environmental Health Sciences (USA), Duke University (USA), UNAM University (Mexico) and Institute of Bichemistry and Biophysics (Poland). Role: Partner Damian Gawel Centre of Postgraduate Medical Education Marymoncka 99/103 01-813 Warsaw, Poland Tel: +48 795-302-760 Email: [email protected] Horizon Europe Tackling Diseases and Antimicrobial Resistance (AMR)
- 101. Proposed Approach Understanding of the problem ● Pandemics are not possible to predict but we can be more prepared ● Sentinel strategies to follow microorganismal genetic material should be part of an inclusive pandemic alarm system Part of the Scope to address ● Implementation of an Open database of expanding set of viral and bacterial genetic markers. ● Proactive tracking of viral and bacterial genetic material. ● Using a variety of sample sources: environment, agricultural, community, hospital. Type of partners ● Partners with access to environmental, agricultural, community and hospital settings. Organisational Capabilities Skills, capabilities, and facilities ● Molecular cloning, genotyping and phenotyping ● Management of complex synthetic biology workflows ● Applied bioinformatics ● High throughput capabilities Type of organisation and benefits ● We are part of an academic institution ● We do not work for profit ● We are under continuous methodological and technological developmental and innovation Experience Previous, relevant, work or track record ● Extensive experience in biological engineering: six years of active work with 341 synthetic biology project carried out to completion. Ability to attract the ‘Big Names’ in the sector (e.g. leading academics, major thought leaders) ● Our umbrella institution, the University of Liverpool, is a big name in itself ● We can attract certain other higher education academic and industrial Administrative Information Coordinator or Partner: ● Either. Depending on the skill sets and experience of those involved Contact details: GeneMill, J. Enrique Salcedo-Sora, Manager, [email protected], 0151 7946455, United Kingdom HORIZON-HLTH-2022-DISEASE-07-02 Pandemic Preparedness
- 102. Proposed Approach What is your understanding of the part of the problem you can solve? Regarding the topic we can assume clinic and recruitment WP What part of the Scope do you want to address? We can realize biomedical research and recruitment of patients regarding rare immunological diseases (15) If you are looking for partners, what type of partners are you looking for? We are searching for a coordinator partner which is searching for a clinical partner in the field of rare immunological diseases. Organisational Capabilities What skills, capabilities, facilities does your organisation have that will be vital for this project? • We have a big potential in recruiting patients since we manage two hospitals. • We have a diverse expertise when speaking about our research groups. • We can address all work packages related to the clinical field in all of its phases and spheres. We are part of the public Health Andalusian Service. In this framework, IBIMA is the research Institute of Málaga province, coordinating research and innovation of the two main hospitals of the region. Experience We have previous experience in all the roles in H2020 projects. We have cooperation's with the most important public bodies of Málaga (University of Málaga, Council of Málaga, technological park of the city, and to different rare diseases associations). Also, as we are part of Health Andalusian Service we can cooperate with support infrastructures such as the Andalusian Network of design of advanced therapies, Centre of genomic and oncologic research of Andalusia, biotechnology and nanotechnology Andalusian centre, etc.. At European level we collaborate with partners such Nottingham University, Paul- Ehrlich-Institute, university of Bournemouth and many more Administrative Information We want to be a partner Your contact details including: Aitor Rando Rodán, [email protected] – +34 686 39 21 74 Spain Your organisation’s PIC: 998029218 HORIZON-HLTH-2022-DISEASE-06-04-two-stage - Development of new effective therapies for rare diseases
- 103. Proposed Approach Treatment of type 1 diabetes and multiple sclerosis by increasing suppressive function of gut immune system and blocking autoimmunity. Treg-binding protein coated nanoparticles containing AhR ligand will be applied orally to induce Treg function. Alternatively, genetically engineered plants that overproduce AhR ligand will be used to make functional food. Looking for partners that can perform microbiota and metabolomics analysis. Organisational Capabilities Animal breeding facility, zebra fish facility, Cell and molecular biology units, Unit for cytometry (FACS ARIA III sorter), Microscopy (confocal), Financial and Administrative office, Research Management Unit, IT sector. IBISS is an academic organisation that entails vivid scientific networking and stimulates cooperation with international partners and provides full logistic support. Overheads from the projects are used to upgrade IBISS research facilities by purchasing novel and high-cost equipment and for training employees in state-of-the-art techniques. Experience 1. Institute for Biological Research (IBISS), Serbia – experts in the pre-clinical evaluation of potential therapeutics (animal models of autoimmune diseases, multi-parameter flow cytometry, cell purification by sorting, immunoblot, RT-qPCR, fluorescent immunohistochemistry). 2. University of Ioaninna, Greece – experts in biochemical characterization of plant-derived compounds and for synthesis of novel compounds with the required scaffolds. 3. ICREA & Institut Catala de Nanociencia i Nanotecnologia, Spain – experts in nanotechnology 4. University of Tours, France – experts in plant genetic engineering. IBISS has a unique position in pre-clinical evaluation research area as it has in-house breeding facility and strict, but rapid Ethical committee approval procedures for the animal usage. We need help with Regulatory and Health Technology Assessment (HTA) strategy Administrative Information I am planning to be a Coordinator. Contact details: Ivana Stojanović [email protected] +381600721372 Serbia PIC 998386760 HORIZON-HLTH-2022-DISEASE-06-02-two-stage Pre-clinical development of the next generation of immunotherapies for diseases or disorders with unmet medical needs AhR ligand Specific Treg-binding protein AhR Treg OR AhR-overexpressing functional food CNS Pancreas
- 104. Proposed Approach AMR (antimicrobial resistance) presents risks of becoming the next pandemic, with both direct and indirect detrimental effects on the health of populations. By combining recent advances in sequencing with a better understanding of the genetic determinants of AMR, I propose to develop a real-time point-of-care diagnostic tool that can a) identify the microbial species responsible for the infection and b) determine its antimicrobial resistance profile in under 4 hours (vs. the current standard of 48 hours), directly from sputum or blood sample. If successful, this proposal would revolutionize the current clinical management of (bacterial) infectious disease, obviating the need for broad-spectrum antibiotics and improving outcomes. This proposal addresses the “better methodologies and diagnostics that allow timely and accurate diagnosis” part of the Scope. It can also be part of a larger proposal for an AMR-focused network. Organisational Capabilities My combined expertise in AMR, next-generation sequencing (NGS) and machine learning (ML) makes me an ideal contributor to a project on real-time species identification and AMR diagnosis using NGS. I seek partners with expertise in developing medical diagnostics, especially in low-resource settings. Imperial College London is an internationally reputed academic institution and provides world- class research support to its staff members. Experience I was the lead PI on several large-scale AMR grants in North America prior to moving to the UK. I have long-standing connections with the World Health Organisation (WHO) and have worked with several start-up companies in the field of diagnostics and AMR. I was one of the leading scientists behind the development of the recently published WHO catalogue of mutations associated with drug resistance in Mycobacterium tuberculosis, the world’s largest infectious killer. Administrative Information I am happy to be the Coordinator or a Partner. Please don’t hesitate to contact me with your ideas: Dr. Leonid Chindelevitch [email protected] +44-7389896780 Department of Infectious Disease Epidemiology Imperial College London United Kingdom Pandemic Preparedness, AMR (Leonid Chindelevitch)
- 105. 1. Proposed Approach What part of the Scope do we want to address? • Development and validation of novel diagnostics and countermeasures for virus families of pandemic potential – specifically RNA viruses • Development of standardised pre-clinical research assays and protocols • Development of Precision biomarkers /diagnostics for virus families of pandemic potential If you are looking for partners, what type of partners are you looking for? • Partners with novel anti-viral targets to validate and exploit. • Partners with novel therapeutics that require translational data • Partners with novel rapid diagnostic technologies 2. Organisational Capabilities What skills, capabilities, facilities does the Catapult have that will be vital for this project? • A Biosafety Level-3 (BSL3) national facility for research, testing and validation of new diagnostics, biomarkers and innovative therapeutics for viruses with pandemic potential • BSL3 capabilities: Complex 3D cell models; cell sorting, live imaging, screening assays; clinically relevant tissues and sample and pathogen strains • Downstream bioanalysis for biomarker development / target validation / MOA studies: ― spatial mass spec and spatial transcriptomics ; genomics; advanced microscopy; integrated bioinformatics MDC is an RTO - a not-for-profit organisation funded by the UK government and our community. This financial independence allows us to operate at pace and scale. 3. Experience What previous, relevant, work or track record do we bring to the team? The MDC team have decades of experience in medicines research and translation. Since 2018, MDC has: • Participated in 160 partnered projects with 86 organisations across the UK • Enabled partners working with MDC to raise over £50 million in new venture investment • Delivered the largest diagnostics laboratory testing project in UK history (SARS-CoV2) Specific large pharma experience working with pandemic projects (PI on DARPA and BARDA projects) for Influenza and SARS-CoV2, vaccines and therapeutics. 4. Administrative Information Are you planning on being the Coordinator or a Partner? Partner Contact details: Helen Bright Head of Infection Biology Medicines Discovery Catapult [email protected] HORIZON-HLTH-2022-DISEASE-07-02: Pandemic preparedness
- 106. Proposed Approach Integrating synthetic chloride transporters and channels in therapies for chloride channelopathies The exchange of anions between the living cell represents one of the most fundamental life- sustaining phenomena, and many diseases are associated with defected chloride anion transport. Hence, the design of synthetic anion transporters and channels is essential for treatment of chloride channelopathies such as Best disease, Bartter's syndrome, Dent's disease, and cystic fibrosis diseases. More specifically, we wish to tackle the problem of chloride channelopathies. Our research has developed synthetic chloride transporters and artificial chloride channels that can be the perfect candidates for channelopathies therapy and act as a valinomycin-like transporter, which could be exploited in biomedical applications. We are currently looking for collaborations to use these attractive synthetic anion transporters/ channels for in-vitro studies to transfer basic academic knowledge into more applied research. That includes using them in vesicle assays, evaluating anion transport activity in cystic fibrosis (CF) cells or other types of rare diseases, or integrating them as part of an artificial device that can mimic the role of CLC channels in malfunctioning cells. Organisational Capabilities The Open University of Israel (OUI) has extensive experience in EU collaborative projects where OUI researchers have always held responsibilities as WP leaders and Task leaders. European projects in which the OUI has participated in the past include FP6 and Horizon 2020 programs. The Open University of Israel (OUI) is an academic institute with many research activities. The Research and Development Authority is experienced with providing the financial and administrative management for the research activity and the space for disseminating results in workshops and meetings and supporting publication costs. Experience Our research group has developed a new family of cavitands named hetero-Bambusurils (BUs), effective anion-binders, and have been used as a key component in designing synthetic anion transporters. Hence, We have proven experience in organic synthesis and control chemical modifications to afford the proper properties required from the transporters: hydrophobicity, lipophilicity, water solubility, and degree of affinity binding to the target analyte. We are also bringing knowledge on material characterization methods as well as skills in isolation and purification processes. This research has been presented in many scientific conferences, including the ICCBs and ISMSCs and produced many collaborations within Europe (Prof. Hagan Bayley, Oxford University, UK and Prof. Jurriaan Huskens, Twente University, Netherlands), Chinna (Prof. Jinqiu Liu, Jillin University) and Australia (Prof. Philipe A. Gale, Sydney University). Administrative Information I am planning on being a Partner and can act as a WP Leader. Prof. Ofer Reany Department of Natural Science, The Open University of Israel E-Mail: [email protected]; Mobile: +972-52-8310422 Organisation’s PIC: 998334477 HORIZON-HLTH-2022-DISEASE-06-04-two-stage: "Development of New Effective Therapies for Rare Diseases"
- 107. Development of antimicrobial peptides (AMPs) based on toxins from toxin-antitoxin (TA) systems We use toxins from bacterial TA systems as lead compounds for the development of antimicrobials with novel mechanisms of action. Our work is, therefore, ideally suited to the upcoming Therapeutics Call as part of JPIAMR. What we can address We observe that these TA system based peptides and our novel derivatives leads to potent antimicrobials with hypothetically novel mechanisms of action. We have already shown that they are active against AMR strains with MICs from the low micro molar to high nano molar range depending on the bacterial strains and conditions of the assay. Partners We are looking for partners with complementary expertise. This includes: peptide chemists to increase the range of derivatives we can explore in our assays, in vivo experts to guide formulation and experimental setup in murine in vivo as well as to inform about selecting disease models and commercial actors to guide our choices to expedite commercialisation. Organisational Capabilities Our strengths are in vitro testing of AMPs. This includes MIC analysis (Mueller-Hinton / Whole blood) across a broad range of bacterial species (resistant and wt), hemolysis and human cell line toxicity determination to calculated our probable therapeutic window. Additionally, we calculate propensity for resistance development amongst many other assays. We are an academic organisation interested in the translation of our fundamental understanding of TA systems to produce new antimicrobials. We hypothesise that these novel leads will lead to AMPs with novel mechanisms of action. Experience We have a long track record on working on characterisation and functional studies of DNA damage- inducible TA systems from E. coli. Our translational activities have involved trying to harness the toxicity of the toxins to produce AMPs. We have subsequently used our experience to expand the number of toxins we are currently examining. We currently have peptides that are effective at high nano-molar concentrations, peptides with no observable resistance development over the course of the one month experiment as opposed to the antibiotic controls, peptides that are stable in whole blood and resist the action of proteases. Administrative Information We can act as both a coordinator or a partner depending on the situation Your contact details including: James Booth [email protected] +47 41045852 Norway JPIAMR Therapeutics - James Booth
- 108. Proposed Approach What is your understanding of the part of the problem you can solve? To make effective therapeutic vaccines What part of the Scope do you want to address? Innovation and integration of expertise and capabilities, including alignment of preclinical and clinical models, biomarker studies and new vaccine approaches from discovery to late stage development, from bench-based research to clinical development of promising preventive candidates. If you are looking for partners, what type of partners are you looking for? • Opportunities to use our platform for novel vaccines – cancer immunotherapy & infectious diseases • Novel manufacturing for recombinant peptides • Improved pre- and post-clinical testing • Access to novel adjuvants • Novel formulations Organisational Capabilities What skills, capabilities, facilities does your organisation have that will be vital for this project? • Access to university laboratories • Scientific knowledge – >25 years in immunology Is your organisation academic, SME, big business, etc (and explain the benefits to this project of whichever you are) SME – offering a vaccine platform technology that can accelerate new cancer and disease vaccine development Experience What previous, relevant, work or track record can you bring to the team? First OVM vaccine in Phase 1 Clinical Trial for cancer Include your ability to attract the ‘Big Names’ in the sector (e.g. leading academics, major thought leaders) Scientific Advisory Committee includes Professor Sir Andrew McMichael. Trial sites include UCLH, Christie, Oxford, Velindre & Sarah Cannon. CONFIDENTIAL INFORMATION Administrative Information Are you planning on being the Coordinator or a Partner? PARTNER CONTACT DETAILS: William Finch, CEO E: [email protected] T: 00 44 (0)1865 784074 UK PIC TBC OXFORD VACMEDIX – Novel vaccine platform -Cluster 1 Destination 3
- 109. Proposed Approach Understanding: To understand our ability to prepare for the AMR pandemic, we need to oversight of ongoing & recent research activities and capabilities. In turn this will identify knowledge gaps and areas of weakness and help to coordinate a trans-national approach. Scope: Build a coordinated knowledge base of AMR research activities across EU & neighbouring countries and how they contribute to AMR National Action Plans. In turn work out where to invest effort for pandemic preparedness. Partners: EU+ nationals who have oversight of their own NAPs to help draw together common knowledge Organisational Capabilities Skills, capabilities, facilities: Scotland’s Rural College (SRUC) has a range of expertise in agri-food production from research to policy and human health. SRUC has a track record for producing academic, policy and industry relevant outputs. Type: SRUC is a higher education academic & research institution, > 1300 staff member, cover whole Scotland. Experience Track record: I led a team to generate a register of AMR-related research activities associated with Scotland over the last 5 years, and mapped them to the UK AMR NAP commitments. The project took a One Health approach to cover all relevant sectors. My own expertise is in molecular bacteriology, on transmission pathways of AMR and pathogenic bacteria. Attract the ‘Big Names’: the team comprised stakeholders from all sectors including Scottish Government; Scottish NHS; centres of expertise for animal epidemiology (EPIC) and water (CREW); environmental protection agency (SEPA); food standards agency (FSS). Academic input covered human health, animal health, plant health, water, wildlife and food. My own research is internationally recognised, with large-scale grants, and well networked inc. EU COST Action. Administrative Information My contribution: as a Partner Contact details: Prof. Nicola Holden [email protected], +44 1224711090 Aberdeen, Scotland, UK SRUC PIC: 999899669 HORIZON-HLTH-2022-DISEASE-07-02 Pandemic preparedness
- 110. Proposed Approach • Invasive fungal infections cause life-threatening infections in IC and critically ill patients • High mortality rate and limited choice of antifungal drugs • Urgent need to develop novel first-in-class therapies • SBF has developed human antifungal antibodies with proven therapeutic efficacy in mouse models - >80% improved survival and 3 log10 killing • For our most advanced leads, target A is pan-fungal and target B is C. albicans specific • Targets involved in stress response & do not have murine or human homologues Project Scope • Explore the possibility of pre-clinical development of the lead mAbs • PK/PD studies, Immunogenicity and Biophysical characterisation, CMC and toxicity studies • Join an existing consortium with European partners / new consortium Organisational Capabilities • Antibody discovery from human and immunised sources • Extensive experience in antibody engineering and conducting in vitro & ex-vivo characterisation • Academic experts in medical mycology & fungal infection biology (Prof C Munro, Aberdeen Fungal Group) • Access to mouse infection models for PoC studies • State-of-the-art microscopy, proteomics & flow cytometry facilities • Industry partner has a portfolio of products in preclinical and clinical development Our’s is a team of academics from the University of Aberdeen and the SME partner Infex Therapeutics. Team members have a strong track-record in successfully developing academic research outputs into commercially viable products. Experience • We have developed a platform technology which can generate therapeutic human mAbs to various fungal pathogens ( Patent protected) • Scottish Biologics Facility is a leading recombinant antibody generation centre • Several antibody leads in PoC animal models and immunodiagnostic development (Alzheimer's Disease, Infectious diseases, liver fibrosis) • Aberdeen Fungal Group has extensive experience studying fungal cell wall biosynthesis and its role in pathogenesis • Industry partner Infex therapeutics with expertise in anti-infectives drug discovery Administrative Information Are you planning on being the Coordinator or a Partner? Partner Your contact details including: Dr Soumya Palliyil Head of Scottish Biologics Facility University of Aberdeen [email protected] What country are you from - UK Your organisation’s PIC - 999929448 Horizon Europe Tackling Disease and AMR – Cluster 1 Destination 3 and 5
- 111. Proposed Approach We have a consortia of Chemists, Materials Scientists, Microbiologists, Social Scientists and Artificial Intelligence and Machine Learning specialists, interested in the development membrane active antimicrobial technologies. E.g. This patented technology platform has been shown to: 1. Morphing Multifunctional Material systems that undergo triggerable material changes from molecular dimers, to spherical aggregates and hydrogel fibres while retaining biological activity; 2. antimicrobial agents and agents to increase/regenerate the efficacy of current antimicrobial agents. Key publications: Chem. Sci. 2017, 8, 7620; J. Mat. Chem. B 2020, 8, 4694; ChemMedChem 2020, 15:22, 2193; Molecules 2020, 25:18, 4126; RSC Adv., 2021, 11, 9550. We are looking for partners to: (i) help apply and (ii) develop novel antimicrobial technologies to application. Organisational Capabilities My organisation is an acedemic institution. What we can offer: • Access to SSA technology. • Chemical synthesis facilities. • Microbiology/Microscopy facilities. • Patch clamp facilities. • Assays to enable the study of membrane:molecule interactions. • Expertise in molecular association and self-association. Experience In 2019 we launched an international network to support equality and diversity within the chemical sciences, currently > 1,200 members: https://www.womeninsuprachem.com/ Angew. Chem. Int. Ed., 2021, 60, 11572. We currently support consortia that has a line of site to the clinic, with over 30 active international members supporting this effort, including individuals with expertise in data curation, artificial intelligence and machine learning. This effort is further supported by UKHSA and industrial members. We have developed consortia that have lead individual bids worth £20 million in the therapeutic sector and included a 2021 Nobel prize winner. Administrative Information We are happy to be either a Coordinator or a Partner. My contact details: Name: Jennifer Hiscock Email: [email protected] Phone number: +44(0)1227 816467 Home country: UK Institution: University of Kent Novel molecular antimicrobial technologies Your Organisation Logo / Brand
- 112. Proposed Approach Speed up development of new vaccines against infectious diseases in humans. Pre-clinical vaccine testing using in vitro human immune tissue model system Partners: vaccine developers Organisational Capabilities Providing a lab vaccine testing system/service for new vaccine development. University: academic& research institution Experience: Using in vitro human immune tissue/cell culture system testing new vaccines, results closely relevant to humans Administrative Information As a study Partner Your contact details including: Name: Dr Qibo Zhang Email : [email protected] Phone: 0044 1517959677 UK Using an in vitro human immune tissue culture system for new vaccine testing/development. University of Liverpool Model advantages • Both T cell immunity & antibody responses • Primary and memory responses • Effect of pre-existing immunity & age on response • Close relevance to human in vivo response • A great system for testing vaccines, & adjuvants